Abstract

Dysfunctional uterine bleeding (HMB) is a common gynaecological disorder where patients usually end up in hysterectomy. Menorrhagia is a symptom of abnormal vaginal bleeding. Medical management with NSAIDS and hormones have their inherent side effects. Ormeloxifene (also known as centchroman) is one of the selective oestrogen receptor modulators or SERMs, a class of medications that acts on the oestrogen receptor. It is best known as a non-hormonal, non-steroidal oral contraceptive, which is taken once per week. Ormeloxifene is anti-proliferative drugs, which reduce production of various endometrial derived local factors, and corrects menorrhagia with decrease menstrual blood loss (MBL) and clots. This is a prospective observational study done during April 2023 to June 2023. 100 patients between the age group 25-45 years, clinically diagnosed with DUB were taken into study. 50 patients were treated with Ormeloxifene and 50 with Norethisterone. Ormeloxifene 60 mg was administered orally twice a week for first 12 weeks and then once in a week for next 12 weeks. Norethisterone 5 mg twice a day from day 15-25 of cycle was administered. MBL was measured using pictorial blood loss assessment chart (PBAC), blood hemoglobin. The median difference between pretreatment and post-treatment PBAC score and Hemoglobin was found to be significant in Ormeloxifene group. Ormeloxifene is a cost-effective effect therapy.

Description